Microvascular endothelial scavenger receptor class B type I protects against heart failure with preserved ejection fraction by inhibiting T-cell cardiotropism.
Heart researchers discovered an immune pathway that drives a common form of heart failure, opening new treatment possibilities.
This EMBO Mol Med study identifies endothelial scavenger receptor SR-BI as a gatekeeper protecting the heart from T-cell-mediated inflammation that drives HFpEF, a condition with limited treatment options. The finding opens a new immune-endothelial axis as a therapeutic target for HFpEF.
What the study was
- Study design
- Mechanistic study in preclinical animal model
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- EMBO molecular medicine
Why it surfaced
Novel immune-endothelial mechanism for HFpEF (EMBO Mol Med); capped at 5 per non-human study rule. HFpEF is a major unmet need condition.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.